Oncotarget cover image

Oncotarget

HER2-low and HER2-zero in Breast Cancer Between Prognosis, Prediction and Entity

Jul 16, 2024
Researchers Marcus Schmidt, Hans-Anton Lehr, and Katrin Almstedt discuss the impact of HER2 in breast cancer prognosis and treatment. They challenge conventional beliefs by exploring the responsiveness of HER2-low and HER2-zero tumors to Trastuzumab-based therapies.
02:41

Podcast summary created with Snipd AI

Quick takeaways

  • HER2 positivity in breast cancer prognosis can lead to positive outcomes with targeted therapies like trastuzumab.
  • Trastuzumab-based therapies can benefit HER2-negative breast tumors, challenging conventional treatment beliefs.

Deep dives

Her 2 Positivity in Breast Cancer

Research by Marcus Schmidt, Hans Anton -Lehr, and Katrin Olmstedt delves into the significance of her 2 positivity in breast cancer prognosis. The study revealed positive outcomes in both advanced and early stages, challenging the notion that her 2 negative tumors do not benefit from Trastuzumab-based therapy.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode